Reconciling IPRs and openness in biobanking
(2016) In European Intellectual Property Review 38(1). p.1-4- Abstract
- This opinion argues that carefully drafted IPR-policies could be used to protect the substantial investments made by biobanks in the collection of HBM and data while at the same time allowing scientists to share information and to seek IPRs on downstream inventions resulting from the use of such collections. We also recognize that the feasibility of IPR-policies depends on the specific types, set-ups and goals of biobanks and that some biobanks might have good reasons to refrain from being involved in IPRs. In many cases, however, an appropriate balance of the IPR-user modalities will be crucial to enhance translational medicine.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/e1ed4b1e-98df-4299-82cd-5bcd12600b5d
- author
- Verlinden, Michiel ; Minssen, Timo LU and Huys, Isabelle
- publishing date
- 2016-01-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Faculty of Law, Open innovation, biobanking, ipr
- in
- European Intellectual Property Review
- volume
- 38
- issue
- 1
- pages
- 4 pages
- publisher
- Sweet & Maxwell
- ISSN
- 0142-0461
- language
- English
- LU publication?
- no
- id
- e1ed4b1e-98df-4299-82cd-5bcd12600b5d
- date added to LUP
- 2020-12-16 14:24:05
- date last changed
- 2020-12-28 09:51:30
@article{e1ed4b1e-98df-4299-82cd-5bcd12600b5d, abstract = {{This opinion argues that carefully drafted IPR-policies could be used to protect the substantial investments made by biobanks in the collection of HBM and data while at the same time allowing scientists to share information and to seek IPRs on downstream inventions resulting from the use of such collections. We also recognize that the feasibility of IPR-policies depends on the specific types, set-ups and goals of biobanks and that some biobanks might have good reasons to refrain from being involved in IPRs. In many cases, however, an appropriate balance of the IPR-user modalities will be crucial to enhance translational medicine.}}, author = {{Verlinden, Michiel and Minssen, Timo and Huys, Isabelle}}, issn = {{0142-0461}}, keywords = {{Faculty of Law; Open innovation; biobanking; ipr}}, language = {{eng}}, month = {{01}}, number = {{1}}, pages = {{1--4}}, publisher = {{Sweet & Maxwell}}, series = {{European Intellectual Property Review}}, title = {{Reconciling IPRs and openness in biobanking}}, volume = {{38}}, year = {{2016}}, }